

## Previous Seminars

2018 - 2019

03 June

*Effects of physician-industry interactions on treatments: the case of heart attacks*

Sofia Amaral-Garcia, Postdoc Researcher at Hasselt University in the research group Economics and Public Policy

16 May

*Opioid analgesics consumption in France*

Ilaria Natali, Teaching Assistant for Advanced Industrial Organization, ULB

29 April

*Market access of pharmaceutical innovation: international R&D, high prices and national competent authorities*

Philippe Van Wilder, Professor in health economics and HTA at Ecole de Santé Publique, ULB

18 February

*Subsidized Health Insurance and Healthcare Utilization: new evidence from a large-scale field experiment*

Raf Van Gestel, Assistant Professor, Erasmus School of Economics & Erasmus School of Health Policy and Management

21 January

*Therapeutic drug monitoring of biologics: where to start, where to end?*

Lynda Grine, Doctor-assistant at Ghent University and Research Associate at the Dermatology Department of Ghent University Hospital

10 December

*Scientific, regulatory, and economic challenges facing the implementation of phage therapy and the Belgian model*

Bob Blasdel, Research Director for Vesale Pharma

30 November

*The case of a multi-drug resistant infection*

[Link to program](#)

26 November

*Precision oncology: how to structure the continuum of clinical research into healthcare for rationale access to anti-cancer treatment*

Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer

12 November

*Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets*

Georges Siotis, Associate Professor at the Economics Department of Universidad Carlos III de Madrid and CEPR Research Fellow

29 October

*Towards new partnerships in the healthcare sector*

Wim Van Haverbeke, Professor of Innovation Management & Strategy at the Hasselt University

08 October

*Vaccines: how to value them, how to price them?*

Michel Dewilde, MDWConsultant, former Senior Vice President R&D, Sanofi Pasteur

01 October

*Measuring mortality in conflicts and disasters: why does it matter?*

Debarati Guha, Director of the Centre for Research on the Epidemiology of Disasters (CRED) and Professor at the School of Public Health (UCL)